

Steven F Powell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4803220/publications.pdf>

Version: 2024-02-01

10
papers

8,712
citations

1040056

9
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

10610
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma. <i>Investigational New Drugs</i> , 2022, , 1.	2.6	15
2	Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 2499.	3.7	2
3	Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial. <i>Oral Oncology</i> , 2021, 115, 105173.	1.5	15
4	Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1883-1892.	1.1	93
5	Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2427-2437.	1.6	88
6	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 1915-1928.	13.7	1,804
7	24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 124-129.	1.1	187
8	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	27.0	4,701
9	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1542-1549.	1.6	527
10	Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. <i>Lancet Oncology</i> , The, 2016, 17, 1497-1508.	10.7	1,279